TELUS: Health Drug Data Trends & National Benchmarks Report – August 2018

The story of drug plans is increasingly two-sided: on the one side are higher-cost specialty drugs, which laid claim to 27% of eligible costs in 2017 for just 1% of claimants; on the other side are traditional non-specialty drugs, where annual growth rates for costs are flat or declining, while utilization slowly climbs. To continue reading click the link below.

Download the full report here

Previous Reformulary Group: ReModel Sample Report – May 2017